Advertisement
Canada markets open in 9 hours 28 minutes
  • S&P/TSX

    21,837.18
    -11.97 (-0.05%)
     
  • S&P 500

    5,149.42
    +32.33 (+0.63%)
     
  • DOW

    38,790.43
    +75.66 (+0.20%)
     
  • CAD/USD

    0.7382
    -0.0007 (-0.09%)
     
  • CRUDE OIL

    82.52
    -0.20 (-0.24%)
     
  • Bitcoin CAD

    89,262.93
    -2,755.52 (-2.99%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,164.00
    -0.30 (-0.01%)
     
  • RUSSELL 2000

    2,024.74
    -14.59 (-0.72%)
     
  • 10-Yr Bond

    4.3400
    +0.0360 (+0.84%)
     
  • NASDAQ futures

    18,164.50
    -67.00 (-0.37%)
     
  • VOLATILITY

    14.33
    -0.08 (-0.56%)
     
  • FTSE

    7,722.55
    -4.87 (-0.06%)
     
  • NIKKEI 225

    39,859.89
    +119.45 (+0.30%)
     
  • CAD/EUR

    0.6787
    -0.0005 (-0.07%)
     

Lonza's full-year core EBITDA up 20.7% on vaccine demand

FILE PHOTO: Logo of Swiss contract drug maker Lonza is seen in Basel

By Ludwig Burger

(Reuters) -Swiss drug contract manufacturer Lonza said core earnings gained 20.7% in 2021, shored up by demand for the substances it supplies for new mRNA COVID-19 vaccines.

Full-year core earnings before interest, tax, depreciation and amortisation (EBITDA) rose to 1.67 billion Swiss francs ($1.82 billion), up from 1.38 billion a year earlier, it said in a statement on Wednesday. That was broadly in line with an analyst consensus posted on its website.

The company, which is a key supplier of vaccine maker Moderna, is stepping up investments as it banks on long-term growth in the biopharmaceuticals sector well beyond the pandemic. [nL8N2R81GF]

ADVERTISEMENT

For this year, Lonza predicted "low to mid-teens" sales growth, when excluding currency swings, as well as core EBITDA margin improvement from 30.8% in 2021.

(Reporting by Ludwig BurgerEditing by Riham Alkousaa, editing by Kirsti Knolle)